Medovate and JEB Technologies bring UK Innovations to the global stage

From the United Kingdom to North and South America, Medovate and JEB Technologies are bringing a new wave of medical innovation to the global stage.  Following a year of expansion, new milestone distributor partnerships have been concluded for their SAFIRA system in Italy, Slovenia, Croatia, Serbia, Austria and the Middle East. In addition, partnerships for their CamPROBE solution have been concluded in Australasia and Brazil, with promising evaluations ongoing in Europe.

Medovate has just returned from North America this past weekend from the prestigious PGA79 PostGraduate Assembly in Anesthesiology event in New York, where it showcased its revolutionary technologies and discussed the latest medical innovations in development. This event demonstrated how the companies are bringing UK engineered solutions to the forefront of anaesthesia and surgical care.

SAFIRA – short for ‘SAFer Injection for Regional Anaesthesia’ is redefining how anaesthetists approach precision, safety, and control in regional anaesthesia peripheral nerve block procedures.  By streamlining the process, SAFIRA reduces the reliance on additional personnel, helps optimise workflow efficiency and supports consistent delivery of local anaesthetic with a built-in pressure limiter, aimed at improving patient safety. Its intuitive design empowers clinicians with full control making regional anaesthesia simple, accessible and cost-effective.

CamPROBE, entering the Latin America medical arena, is a simple and cost-effective solution intended to facilitate transperineal prostate biopsies under simultaneous local anaesthetic delivery.  With new distributors, as well as promising European evaluations, CamPROBE is positioned to support wider adoption of prostate biopsy techniques and contribute to improving prostate cancer diagnostic processes.

By joining forces, JEB Technologies and Medovate combine manufacturing excellence with commercial execution, strengthening their ability to deliver medical innovations on a worldwide basis.  The collaboration is set to drive further medical technology advancements and product launches in 2026.